Navigation Links
Future hope for patients with breast cancers resistant to tamoxifen
Date:6/16/2008

Researchers have found a new family of therapeutic agents that interferes with the ability of estrogen to stimulate the growth of breast cancer cells. The results of the new study will be presented by Nicole Patterson at The Endocrine Society's 90th Annual Meeting in San Francisco.

The cell-based study suggests that a small-molecule therapeutic called TPBM and related compounds are likely to be effective against breast cancers that depend on estrogen to grow (called estrogen receptor-positive) but that are resistant to current therapies, team leader David Shapiro, PhD, said.

Shapiro, a biochemist at the University of Illinois at Urbana-Champaign, said at detection, about two-thirds of breast cancers are estrogen receptor-positive, and virtually all of these cancers become resistant over time to the breast cancer drug tamoxifen. In some tamoxifen-resistant tumors, tamoxifen begins to act like estrogen and can actually stimulate tumor growth, he explained.

Therefore, researchers are trying to find new ways to block resistance to drugs such as tamoxifen. Shapiro's team developed a technique to screen for chemical compounds that would inhibit the ability of estrogen and the estrogen receptor protein to bind to DNA and turn on gene expression in breast cancer cells.

"We targeted a different step in the pathway of estrogen action, one that is not targeted by current therapeutics," Shapiro said.

They then tested various agents in estrogen receptor-positive breast cancer cells in the laboratory. The team identified a family of compounds related to TPBM that Shapiro said inhibited the estrogen-dependent growth of breast cancer cells.

"TPBM is highly targeted and has little or no toxic effect on other cellsthose that don't depend on the estrogen receptor," Shapiro said. "Also important, these compounds are effective in breast cancer cells in which tamoxifen acts like estrogen."

Thus, these compounds might prevent tamoxifen-resistant breast cancer from becoming more aggressive. However, Shapiro cautioned that their research is in the early stage. A future step will be testing the new estrogen receptor inhibitors in animal models of breast cancer.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Cancer was one of the best things to happen to me ... but I worry about the future
2. Cancer was one of the best things to happen to me... but I worry about the future
3. Next 10 years crucial to ensure provision of clean water for future generations
4. Future of Behavioral Health Care for New Mexicos Youth Subject of Expert Panel Sponsored by ValueOptions(R)
5. Survivors of childhood Hodgkins lymphoma at higher risk of future health problems
6. Hodgkin Lymphoma Kids Face Greater Risk of Future Problems
7. New study shows sedentary high school girls are at significant risk for future osteoporosis
8. Invest in Your Future With a Spa Visit Today
9. NIDCR strategies for future scientific success
10. Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care
11. AMICAS Focuses on the Future of Radiology IT at SIIM 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... ... the addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. ... consulting firm’s national accounts, from assisting clients with initial vendor selection and pre-implementation ...
(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story of ... the creation of published author, Larry R. Sherman, a retired chemistry professor from the ... as well as four novels. , Though the book opens in 1947, when ...
(Date:8/22/2017)... North Carolina (PRWEB) , ... August 22, 2017 ... ... strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 Leadership ... that have become critical to his definition of “success”: physician leadership development, servant ...
(Date:8/21/2017)... Yorba Linda, Ca (PRWEB) , ... August 22, ... ... for numerous industries, but not without risk to health and safety. By learning ... risks could be eliminated. , In this webinar, attendees will gain a ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
Breaking Medicine Technology: